Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 30198.20 
• Atom Count: 1973 
• Residue Count: 256 
• Unique protein chains: 1

2AX8

Crystal Structure Of The Androgen Receptor Ligand Binding Domain W741L Mutant In Complex With S-1

• DOI: 10.2210/pdb2AX8/pdb

• Classification: TRANSCRIPTION
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): 1 


• Deposited: 2005-09-03 Released: 2005-09-20 
• Deposition Author(s): Bohl, C.E., Miller, D.D., Chen, J., Bell, C.E., Dalton, J.T.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.7 Å
• R-Value Free: 0.248 
• R-Value Work: 0.212 

Literature

Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor

Bohl, C.E., Miller, D.D., Chen, J., Bell, C.E., Dalton, J.T.

(2005) J.Biol.Chem. 280: 37747-37754

• PubMed: 16129672 
• DOI: 10.1074/jbc.M507464200
• Primary Citation of Related Structures:  
  2AXA, 2AX9, 2AX7, 2AX6


• PubMed Abstract: 
  

The mechanism by which the androgen receptor (AR) distinguishes between agonist and antagonist ligands is poorly understood. AR antagonists are currently used to treat prostate cancer. However, mutations commonly develop in patients that convert these compounds to agonists. Recently, our laboratory discovered selective androgen receptor modulators, which structurally resemble the nonsteroidal AR antagonists bicalutamide and hydroxyflutamide but act as agonists for the androgen receptor in a tissue-selective manner. To investigate why subtle structural changes to both the ligand and the receptor (i.e. mutations) result in drastic changes in activity, we studied structure-activity relationships for nonsteroidal AR ligands through crystallography and site-directed mutagenesis, comparing bound conformations of R-bicalutamide, hydroxyflutamide, and two previously reported nonsteroidal androgens, S-1 and R-3. These studies provide the first crystallographic evidence of the mechanism by which nonsteroidal ligands interact with the wild type AR. We have shown that changes induced to the positions of Trp-741, Thr-877, and Met-895 allow for ligand accommodation within the AR binding pocket and that a water-mediated hydrogen bond to the backbone oxygen of Leu-873 and the ketone of hydroxyflutamide is present when bound to the T877A AR variant. Additionally, we demonstrated that R-bicalutamide stimulates transcriptional activation in AR harboring the M895T point mutation. As a whole, these studies provide critical new insight for receptor-based drug design of nonsteroidal AR agonists and antagonists.

---

Organizational Affiliation: 

Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, 43210, USA.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Androgen receptor	A	256	Homo sapiens	Mutation(s): 1  Gene Names: AR (DHTR, NR3C4)
Find proteins for P10275 (Homo sapiens) Go to Gene View: AR Go to UniProtKB:  P10275

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
FHM	A	S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE C17 H14 F4 N2 O5 KJMFOTCDISOHDX-INIZCTEOSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
FHM	Ki: 6.1 - 6.1 nM (99) BINDINGDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.7 Å
• R-Value Free: 0.248 
• R-Value Work: 0.212 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length (Å)	Angle (°)
a = 55.089	α = 90.00
b = 66.107	β = 90.00
c = 69.032	γ = 90.00

Software Package:

Software Name	Purpose
SCALEPACK	data scaling
CNS	refinement
CNS	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2005-09-03 
• Released Date: 2005-09-20 
• Deposition Author(s): Bohl, C.E., Miller, D.D., Chen, J., Bell, C.E., Dalton, J.T.

Revision History 

• Version 1.0: 2005-09-20
  Type: Initial release
• Version 1.1: 2008-05-01
  Type: Version format compliance
• Version 1.2: 2011-07-13
  Type: Version format compliance
• Version 1.3: 2017-10-11
  Type: Refinement description